Role of anti-diabetic medications in the management of MASLD
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Role of anti-diabetic medications in the management of MASLD
-
ナレーター：
-
著者：
このコンテンツについて
The use of anti-diabetic medications such as pioglitazone or GLP-1 receptor agonists in the management of metabolic dysfunction-associated steatotic liver disease (MASLD) is discussed in this podcast. Dr Oliver Tavabie, Deputy Editor at FG and Hepatology Consultant at the Leeds Liver Unit, interviews Drs Scott Isaacs and Paul Brennan. Dr Scott Isaacs is the President of the American Association of Clinical Endocrinology and an Adjunct Associate Professor at Emory University School of Medicine, US. Dr Paul Brennan is a Senior Registrar and Honorary Research Fellow in Hepatology based at Ninewells Hospital, UK. They are authors of the paper "Role of anti-diabetic medications in the management of MASLD”, published online in Frontline Gastroenterology in February 2025.
We hope you enjoy the #FGPodcast. Please follow @FrontGastro_BMJ. Listen to our regular podcasts and subscribe in Apple Podcasts and Spotify. If you enjoy our podcast, please rate us on your chosen platform, and leave us a review on the Frontline Gastroenterology Podcast page on iTunes: https://podcasts.apple.com/gb/podcast/fg-podcast/id942944229